Activation of the PPAR/PGC-1α Pathway Prevents a Bioenergetic Deficit and Effectively Improves a Mitochondrial Myopathy Phenotype

Tina Wenz, Francisca Diaz, Bruce M. Spiegelman, Carlos T Moraes

Research output: Contribution to journalArticle

257 Citations (Scopus)

Abstract

Neuromuscular disorders with defects in the mitochondrial ATP-generating system affect a large number of children and adults worldwide, but remain without treatment. We used a mouse model of mitochondrial myopathy, caused by a cytochrome c oxidase deficiency, to evaluate the effect of induced mitochondrial biogenesis on the course of the disease. Mitochondrial biogenesis was induced either by transgenic expression of peroxisome proliferator-activated receptor γ (PPARγ) coactivator α (PGC-1α) in skeletal muscle or by administration of bezafibrate, a PPAR panagonist. Both strategies successfully stimulated residual respiratory capacity in muscle tissue. Mitochondrial proliferation resulted in an enhanced OXPHOS capacity per muscle mass. As a consequence, ATP levels were conserved resulting in a delayed onset of the myopathy and a markedly prolonged life span. Thus, induction of mitochondrial biogenesis through pharmacological or metabolic modulation of the PPAR/PGC-1α pathway promises to be an effective therapeutic approach for mitochondrial disorders.

Original languageEnglish
Pages (from-to)249-256
Number of pages8
JournalCell Metabolism
Volume8
Issue number3
DOIs
StatePublished - Sep 3 2008

Fingerprint

Mitochondrial Myopathies
Peroxisome Proliferator-Activated Receptors
Organelle Biogenesis
Energy Metabolism
Phenotype
Cytochrome-c Oxidase Deficiency
Adenosine Triphosphate
Bezafibrate
Mitochondrial Diseases
Muscles
Muscular Diseases
Skeletal Muscle
Pharmacology
Therapeutics

Keywords

  • HUMDISEASE

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Physiology

Cite this

Activation of the PPAR/PGC-1α Pathway Prevents a Bioenergetic Deficit and Effectively Improves a Mitochondrial Myopathy Phenotype. / Wenz, Tina; Diaz, Francisca; Spiegelman, Bruce M.; Moraes, Carlos T.

In: Cell Metabolism, Vol. 8, No. 3, 03.09.2008, p. 249-256.

Research output: Contribution to journalArticle

@article{b03edd3d928a403a9c87c9d2e0a5875c,
title = "Activation of the PPAR/PGC-1α Pathway Prevents a Bioenergetic Deficit and Effectively Improves a Mitochondrial Myopathy Phenotype",
abstract = "Neuromuscular disorders with defects in the mitochondrial ATP-generating system affect a large number of children and adults worldwide, but remain without treatment. We used a mouse model of mitochondrial myopathy, caused by a cytochrome c oxidase deficiency, to evaluate the effect of induced mitochondrial biogenesis on the course of the disease. Mitochondrial biogenesis was induced either by transgenic expression of peroxisome proliferator-activated receptor γ (PPARγ) coactivator α (PGC-1α) in skeletal muscle or by administration of bezafibrate, a PPAR panagonist. Both strategies successfully stimulated residual respiratory capacity in muscle tissue. Mitochondrial proliferation resulted in an enhanced OXPHOS capacity per muscle mass. As a consequence, ATP levels were conserved resulting in a delayed onset of the myopathy and a markedly prolonged life span. Thus, induction of mitochondrial biogenesis through pharmacological or metabolic modulation of the PPAR/PGC-1α pathway promises to be an effective therapeutic approach for mitochondrial disorders.",
keywords = "HUMDISEASE",
author = "Tina Wenz and Francisca Diaz and Spiegelman, {Bruce M.} and Moraes, {Carlos T}",
year = "2008",
month = "9",
day = "3",
doi = "10.1016/j.cmet.2008.07.006",
language = "English",
volume = "8",
pages = "249--256",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - Activation of the PPAR/PGC-1α Pathway Prevents a Bioenergetic Deficit and Effectively Improves a Mitochondrial Myopathy Phenotype

AU - Wenz, Tina

AU - Diaz, Francisca

AU - Spiegelman, Bruce M.

AU - Moraes, Carlos T

PY - 2008/9/3

Y1 - 2008/9/3

N2 - Neuromuscular disorders with defects in the mitochondrial ATP-generating system affect a large number of children and adults worldwide, but remain without treatment. We used a mouse model of mitochondrial myopathy, caused by a cytochrome c oxidase deficiency, to evaluate the effect of induced mitochondrial biogenesis on the course of the disease. Mitochondrial biogenesis was induced either by transgenic expression of peroxisome proliferator-activated receptor γ (PPARγ) coactivator α (PGC-1α) in skeletal muscle or by administration of bezafibrate, a PPAR panagonist. Both strategies successfully stimulated residual respiratory capacity in muscle tissue. Mitochondrial proliferation resulted in an enhanced OXPHOS capacity per muscle mass. As a consequence, ATP levels were conserved resulting in a delayed onset of the myopathy and a markedly prolonged life span. Thus, induction of mitochondrial biogenesis through pharmacological or metabolic modulation of the PPAR/PGC-1α pathway promises to be an effective therapeutic approach for mitochondrial disorders.

AB - Neuromuscular disorders with defects in the mitochondrial ATP-generating system affect a large number of children and adults worldwide, but remain without treatment. We used a mouse model of mitochondrial myopathy, caused by a cytochrome c oxidase deficiency, to evaluate the effect of induced mitochondrial biogenesis on the course of the disease. Mitochondrial biogenesis was induced either by transgenic expression of peroxisome proliferator-activated receptor γ (PPARγ) coactivator α (PGC-1α) in skeletal muscle or by administration of bezafibrate, a PPAR panagonist. Both strategies successfully stimulated residual respiratory capacity in muscle tissue. Mitochondrial proliferation resulted in an enhanced OXPHOS capacity per muscle mass. As a consequence, ATP levels were conserved resulting in a delayed onset of the myopathy and a markedly prolonged life span. Thus, induction of mitochondrial biogenesis through pharmacological or metabolic modulation of the PPAR/PGC-1α pathway promises to be an effective therapeutic approach for mitochondrial disorders.

KW - HUMDISEASE

UR - http://www.scopus.com/inward/record.url?scp=50049118173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049118173&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2008.07.006

DO - 10.1016/j.cmet.2008.07.006

M3 - Article

C2 - 18762025

AN - SCOPUS:50049118173

VL - 8

SP - 249

EP - 256

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 3

ER -